Copanlisib safe and active in combination.
Killock D.
Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/s41571-021-00512-1 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för copanlisib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
35 hitsThe PI3K pathway as a therapeutic intervention point in inflammatory bowel disease.
Winkelmann P, Unterweger AL, Khullar D, Beigel F, Koletzko L, Siebeck M, Gropp R.
Immun Inflamm Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/iid3.435NHL Progression Risk Cut with Copanlisib-Rituximab Combo.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-nb2021-0331Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL.
Lancet Oncol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(21)00145-5Update on the role of copanlisib in hematologic malignancies.
Le T, Jerel D, Bryan LJ.
Ther Adv Hematol · review-article; review; journal article · DOI 10.1177/20406207211006027Copanlisib plus Gemcitabine Has Efficacy in Peripheral T-cell Lymphomas.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-rw2021-044Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Keegan NM, Furney SJ, Walshe JM, Gullo G, Kennedy MJ, Smith D, McCaffrey J, Kelly CM, Egan K, Kerr J, Given M, O'Donovan P, Hernando A, Teiserskiene A, Parker I, Kay E, Farrelly A, Carr A, Calzaferri G, McDermott R, Keane MM, Grogan L, Breathnach O, Morris PG, Toomey S, Hennessy BT.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13061225Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Munoz J, Follows GA, Nastoupil LJ.
Target Oncol · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1007/s11523-021-00802-9Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Siddesh A, Sriram D, Zakkula A, Kumar R, Dittakavi S, Zainuddin M, Trivedi RK, Mullangi R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.5015Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P, Follows GA, Mollica L, Nagler A, Özcan M, Santoro A, Stevens D, Trevarthen D, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL, Dreyling M.
Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2020002910Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Chauhan AF, Cheson BD.
Cancer Manag Res · review-article; review; journal article · DOI 10.2147/cmar.s201024Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Yhim HY, Kim T, Kim SJ, Shin HJ, Koh Y, Kim JS, Park J, Park GS, Kim WS, Moon JH, Yang DH.
Ann Oncol · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1016/j.annonc.2020.12.009Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD.
Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1002/cncr.33364Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.
Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K.
Target Oncol · published erratum; correction · DOI 10.1007/s11523-020-00762-6Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J, Yang S, Tian H, Zhang Y, Zhao H.
Cell Death Dis · retracted publication; research-article; journal article · DOI 10.1038/s41419-020-03154-wCombination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer K, Politz O, Eder T, Otto R, Raguse JD, Albers A, Kaufmann A, Tinhofer I, Hoffmann J, Keller U, Keilholz U.
Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.27763Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M, Cheson BD.
Future Oncol · review; journal article · DOI 10.2217/fon-2020-0195Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Magagnoli M, Carlo-Stella C, Santoro A.
Expert Rev Clin Pharmacol · review; journal article · DOI 10.1080/17512433.2020.1787829Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Fang B, Kannan A, Zhao S, Nguyen QH, Ejadi S, Yamamoto M, Camilo Barreto J, Zhao H, Gao L.
Sci Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-020-65637-2Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A, Rosell J, Serna G, Valverde C, Carles J, Nuciforo P, Fletcher JA, Arribas J, Politz O, Serrano C.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-19-1069Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Tarantelli C, Lange M, Gaudio E, Cascione L, Spriano F, Kwee I, Arribas AJ, Rinaldi A, Jourdan T, Berthold M, Sturz A, Sperl C, Margheriti F, Scalise L, Gritti G, Rossi D, Stathis A, Liu N, Zucca E, Politz O, Bertoni F.
Blood Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/bloodadvances.2019000844Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ.
Gynecol Oncol Rep · brief-report; journal article · DOI 10.1016/j.gore.2019.100532Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A, Bhatia R, Chawla P, Anghore D, Saini V, Rawal RK.
Anticancer Agents Med Chem · review; journal article · DOI 10.2174/1871520620666200317105207The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.
Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN.
Cell Death Discov · research-article; journal article · DOI 10.1038/s41420-019-0165-7Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A, Vallejos X, Sebea E, Evans K.
Ann Pharmacother · review; journal article · DOI 10.1177/1060028019833992Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S, Tanaka Y, Tauchi T, Ohyashiki K.
Ann Hematol · journal article · DOI 10.1007/s00277-018-3547-7Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G, Hassenrück F, Hallek M.
Drug Des Devel Ther · comparative study; review-article; review; journal article · DOI 10.2147/dddt.s142406Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah FA, Blaize JP, Bryan LJ.
Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s142264Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [<sup>14</sup>C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.
Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, Reschke S, van der Mey D, Granvil C.
Cancer Chemother Pharmacol · research-article; journal article · DOI 10.1007/s00280-017-3383-9First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.
Ann Oncol · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdw282